Determination of the pharmacokinetics of a single oral dose of trazodone and its effect on the activity level of domestic pigeons (Columba livia)

Marion R. Desmarchelier Département de Sciences Cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, St-Hyacinthe, QC J2S 2M2, Canada.

Search for other papers by Marion R. Desmarchelier in
Current site
Google Scholar
PubMed
Close
 DVM, MSc
,
Francis Beaudry Groupe de Recherche en Pharmacologie Animale du Québec (GREPAQ), Département de Biomédecine Vétérinaire, Faculté de Médecine Vétérinaire, Université de Montréal, St-Hyacinthe, QC J2S 2M2, Canada.

Search for other papers by Francis Beaudry in
Current site
Google Scholar
PubMed
Close
 PhD
,
Shannon T. Ferrell Zoo de Granby, 1050 Blvd David-Bouchard N, Granby, QC J2G 5P3, Canada.

Search for other papers by Shannon T. Ferrell in
Current site
Google Scholar
PubMed
Close
 DVM
, and
Diane Frank Département de Sciences Cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, St-Hyacinthe, QC J2S 2M2, Canada.

Search for other papers by Diane Frank in
Current site
Google Scholar
PubMed
Close
 DVM

Abstract

OBJECTIVE: To determine the pharmacokinetics of a single oral dose of trazodone and its effect on the activity of domestic pigeons (Columba livia).

ANIMALS: 6 healthy adult male domestic pigeons.

PROCEDURES: During the first of 3 experiments, birds received orally administered trazodone at doses ranging from 3 to 30 mg/kg to determine the dose for subsequent experiments. During the second experiment, each bird received 1 dose of trazodone (30 mg/kg, PO). Blood was collected for determination of plasma trazodone concentration before and at predetermined times for 24 hours after drug administration. Pharmacokinetic parameters were calculated by noncompartmental analysis. During experiment 3, birds were instrumented with ultralightweight accelerometers and received orally administered trazodone (30 mg/kg) or an equal volume of water twice at a 48-hour interval. Activity of birds was monitored for 24 hours after administration of each treatment.

RESULTS: No adverse effects were observed. Mean ± SD terminal half-life of trazodone was 5.65 ± 1.75 hours. Plasma trazodone concentrations remained > 0.130 μg/mL for approximately 20 hours. Trazodone did not affect the activity of birds during the first 2 and 15 hours after administration.

CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that oral administration of 1 dose (30 mg/kg) of trazodone to healthy pigeons was safe and resulted in plasma drug concentrations that were similar to those considered therapeutic in humans and dogs for up to 20 hours. Further research is necessary to characterize the pharmacokinetics for repeated doses as well as the clinical effects of trazodone in birds with behavior problems.

Abstract

OBJECTIVE: To determine the pharmacokinetics of a single oral dose of trazodone and its effect on the activity of domestic pigeons (Columba livia).

ANIMALS: 6 healthy adult male domestic pigeons.

PROCEDURES: During the first of 3 experiments, birds received orally administered trazodone at doses ranging from 3 to 30 mg/kg to determine the dose for subsequent experiments. During the second experiment, each bird received 1 dose of trazodone (30 mg/kg, PO). Blood was collected for determination of plasma trazodone concentration before and at predetermined times for 24 hours after drug administration. Pharmacokinetic parameters were calculated by noncompartmental analysis. During experiment 3, birds were instrumented with ultralightweight accelerometers and received orally administered trazodone (30 mg/kg) or an equal volume of water twice at a 48-hour interval. Activity of birds was monitored for 24 hours after administration of each treatment.

RESULTS: No adverse effects were observed. Mean ± SD terminal half-life of trazodone was 5.65 ± 1.75 hours. Plasma trazodone concentrations remained > 0.130 μg/mL for approximately 20 hours. Trazodone did not affect the activity of birds during the first 2 and 15 hours after administration.

CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that oral administration of 1 dose (30 mg/kg) of trazodone to healthy pigeons was safe and resulted in plasma drug concentrations that were similar to those considered therapeutic in humans and dogs for up to 20 hours. Further research is necessary to characterize the pharmacokinetics for repeated doses as well as the clinical effects of trazodone in birds with behavior problems.

Contributor Notes

Address correspondence to Dr. Desmarchelier (marion.desmarchelier@umontreal.ca).
  • 1. Gaskins LA, Bergman L. Surveys of avian practitioners and pet owners regarding common behavior problems in psittacine birds. J Avian Med Surg 2011;25:111118.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2. Seibert LM. Pharmacotherapy for behavioral disorders in pet birds. J Exot Pet Med 2007;16:3037.

  • 3. Visser M, Ragsdale MM, Boothe DM. Pharmacokinetics of amitriptyline HCl and its metabolites in healthy African Grey Parrots (Psittacus erithacus) and Cockatoos (Cacatua species). J Avian Med Surg 2015;29:275281.

    • Search Google Scholar
    • Export Citation
  • 4. van Zeeland YR, Schoemaker NJ, Haritova A, et al. Pharmacokinetics of paroxetine, a selective serotonin reuptake inhibitor, in Grey parrots (Psittacus erithacus erithacus): influence of pharmaceutical formulation and length of dosing. J Vet Pharmacol Ther 2013;36:5158.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5. Ramsay EC, Grindlinger H. Use of clomipramine in the treatment of obsessive behavior in psittacine birds. J Assoc Avian Vet 1994;8:915.

  • 6. Seibert LM, Crowell-Davis SL, Wilson GH, et al. Placebo-controlled clomipramine trial for the treatment of feather picking disorder in cockatoos. J Am Anim Hosp Assoc 2004;40:261269.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 2009;14:536546.

  • 8. Saiz-Rodríguez M, Belmonte C, Derqui-Fernández N, et al. Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety. Pharmacogenomics 2017;18:14911502.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9. Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 1994;4:331355.

    • Search Google Scholar
    • Export Citation
  • 10. Luparini MR, Garrone B, Pazzagli M, et al. A cortical GABA-5HT interaction in the mechanism of action of the antidepressant trazodone. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:11171127.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005;66:469476.

  • 12. Buoli M, Rovera C, Pozzoli SM, et al. Is trazodone more effective than clomipramine in major depressed outpatients? A single-blind study with intravenous and oral administration. CNS Spectr 2017;51:17.

    • Search Google Scholar
    • Export Citation
  • 13. Bossini L, Casolaro I, Koukouna D, et al. Off-label uses of trazodone: a review. Expert Opin Pharmacother 2012;13:17071717.

  • 14. Jay AR, Krotscheck U, Parsley E, et al. Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. Am J Vet Res 2013;74:14501456.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15. Knych HK, Mama KR, Steffey EP, et al. Pharmacokinetics and selected pharmacodynamics of trazodone following intravenous and oral administration to horses undergoing fitness training. Am J Vet Res 2017;78:11821192.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16. Murphy LA, Barletta M, Graham LF, et al. Effects of acepromazine and trazodone on anesthetic induction dose of propofol and cardiovascular variables in dogs undergoing general anesthesia for orthopedic surgery. J Am Vet Med Assoc 2017;250:408416.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17. Gilbert-Gregory SE, Stull JW, Rice MR, et al. Effects of trazodone on behavioral signs of stress in hospitalized dogs. J Am Vet Med Assoc 2016;249:12811291.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18. Gruen ME, Roe SC, Griffith E, et al. Use of trazodone to facilitate postsurgical confinement in dogs. J Am Vet Med Assoc 2014;245:296301.

  • 19. Gruen ME, Sherman BL. Use of trazodone as an adjunctive agent in the treatment of canine anxiety disorders: 56 cases (1995–2007). J Am Vet Med Assoc 2008;233:19021907.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20. Orlando JM, Case BC, Thomson AE, et al. Use of oral trazodone for sedation in cats: a pilot study. J Feline Med Surg 2016;18:476482.

  • 21. Stevens BJ, Frantz EM, Orlando JM, et al. Efficacy of a single dose of trazodone hydrochloride given to cats prior to veterinary visits to reduce signs of transport- and examination-related anxiety. J Am Vet Med Assoc 2016;249:202207.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22. Warnick JE, Wicks RT, Sufka KJ. Modeling anxiety-like states: pharmacological characterization of the chick separation stress paradigm. Behav Pharmacol 2006;17:581587.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23. Lamb RJ, McMillan DE. The effects of some putative antidepressant agents on the schedule-controlled behavior of the pigeon. Psychopharmacology (Berl) 1986;88:368373.

    • Search Google Scholar
    • Export Citation
  • 24. Desmarchelier M, Troncy E, Beauchamp G, et al. Evaluation of a fracture pain model in domestic pigeons (Columba livia). Am J Vet Res 2012;73:353360.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. Philadelphia: Lippincott Williams and Wilkins, 1995;601.

    • Search Google Scholar
    • Export Citation
  • 26.FDA. Bioanalytical method validation guidance for industry. Available at: www.fda.gov/downloads/drugs/guidances/ucm070107.Pdf. Accessed Jul 23, 2018.

    • Search Google Scholar
    • Export Citation
  • 27. Catanese B, Lisciani R. Investigations on the absorption and distribution of trazodone or AF 1161 in rats, dogs and humans. Boll Chim Farm 1970;109:369–373.

    • Search Google Scholar
    • Export Citation
  • 28. Vatassery GT, Holden LA, Hazel DK, et al. Determination of trazodone and its metabolite, 1-m-chlorophenyl-piperazine, in human plasma and red blood cell samples by HPLC. Clin Biochem 1997;30:149153.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29. Nilsen OG, Dale O. Single dose pharmacokinetics of trazodone in healthy subjects. Pharmacol Toxicol 1992;71:150153.

  • 30. Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 1998;26:572575.

    • Search Google Scholar
    • Export Citation
  • 31. Hunter RP, Isaza R. Concepts and issues with interspecies scaling in zoological pharmacology. J Zoo Wildl Med 2008;39:517526.

  • 32. Karhu D, Gossen ER, Mostert A, et al. Safety, tolerability, and pharmacokinetics of once-daily trazodone extended-release caplets in healthy subjects. Int J Clin Pharmacol Ther 2011;49:730743.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33. Mann TM, Williams KE, Pearce PC, et al. A novel method for activity monitoring in small non-human primates. Lab Anim 2005;39:169177.

  • 34. Raj R, Ussavarungsi K, Nugent K. Accelerometer-based devices can be used to monitor sedation/agitation in the intensive care unit. J Crit Care 2014;29:748752.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35. Czerniak R. Gender-based differences in pharmacokinetics in laboratory animal models. Int J Toxicol 2001;20:161163.

Advertisement